Unraveling oxyntomodulin, GLP1's enigmatic brother
Open Access
- 27 September 2012
- journal article
- review article
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 215 (3), 335-346
- https://doi.org/10.1530/joe-12-0368
Abstract
Oxyntomodulin (OXM) is a peptide secreted from the L cells of the gut following nutrient ingestion. OXM is a dual agonist of the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR) combining the effects of GLP1 and glucagon to act as a potentially more effective treatment for obesity than GLP1R agonists. Injections of OXM in humans cause a significant reduction in weight and appetite, as well as an increase in energy expenditure. Activation of GCGR is classically associated with an elevation in glucose levels, which would be deleterious in patients with T2DM, but the antidiabetic properties of GLP1R agonism would be expected to counteract this effect. Indeed, OXM administration improved glucose tolerance in diet-induced obese mice. Thus, dual agonists of the GCGR and GLP1R represent a new therapeutic approach for diabetes and obesity with the potential for enhanced weight loss and improvement in glycemic control beyond those of GLP1R agonists.Keywords
This publication has 141 references indexed in Scilit:
- The Glucagon Receptor Is Involved in Mediating the Body Weight‐Lowering Effects of OxyntomodulinObesity, 2012
- Pioglitazone in Clinical Practice: Where Are We Now?Diabetes Therapy, 2012
- Glucagon and a glucagon‐GLP‐1 dual‐agonist increases cardiac performance with different metabolic effects in insulin‐resistant heartsBritish Journal of Pharmacology, 2011
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutideInternational Journal of Obesity, 2011
- The metabolic actions of glucagon revisitedNature Reviews Endocrinology, 2010
- Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug ScreeningMolecular Pharmacology, 2010
- Obesity treatment: novel peripheral targetsBritish Journal of Clinical Pharmacology, 2009
- Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?British Journal of Pharmacology, 2009
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurrent Medical Research and Opinion, 2007
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007